Integra LifeSciences Holdings Corp. IART trades at a steep valuation discount, while recent margin gains and better operating execution offer support for the earnings outlook. The gap versus industry and market benchmarks gives value investors a reason to look closer.
The trade-off is that revenue growth remains modest, leverage is elevated and regulatory remediation is unfinished. That combination makes execution more important than the headline multiple alone.
IART’s Valuation Offers a Clear Discount
IART trades at 6.96X forward 12-month earnings, compared with 26.19X for its Zacks sub-industry, 21.43X for the broader Zacks Medical sector and 20.50X for the S&P 500. The discount is substantial across each benchmark.
Image Source: Zacks Investment Research
The stock also sits below its five-year median forward multiple of 11.00X. That suggests investors are still assigning a sizable discount for company-specific uncertainty despite the recent improvement in operating performance.
Integra’s Earnings Outlook Shows Measured Growth
The Zacks Consensus Estimate calls for 2026 revenues of $1.68 billion and earnings of $2.46 per share. For 2027, the consensus estimate stands at $1.74 billion in revenues and $2.56 per share in earnings.
Image Source: Zacks Investment Research
Projected earnings growth for the current fiscal year is 10.3%, while projected sales growth is 2.6%. The gap implies that margin delivery and cost execution will carry more weight than top-line expansion in supporting the earnings case.
IART’s Operating Improvements Strengthen the Case
Second-quarter 2026 adjusted earnings of 56 cents per share beat the Zacks Consensus Estimate by 16.7%. Adjusted EBITDA increased 10.1% to $78.4 million, while the adjusted EBITDA margin expanded 160 basis points to 18.7%.
Manufacturing efficiencies, lower remediation spending and margin-improvement initiatives supported the quarter. Integra also expects $25-$30 million of savings in 2026, with another $10-$15 million of annualized savings in 2027.
Competition remains relevant as supply reliability improves. Medtronic plc MDT offers a broad neurosurgery portfolio spanning cranial repair, shunts, powered surgical equipment and navigation, while Stryker Corporation SYK markets neurosurgical technologies including ultrasonic aspirators, high-speed drills and navigation systems. That breadth reinforces the importance of consistent execution for Integra.
Integra’s Debt and FDA Risks Argue for Patience
Net debt stood at $1.60 billion at the end of the second quarter, while total leverage was 4.1X, above management’s 2.5X-3.5X target range. Interest expense rose to $23.0 million from $21.0 million a year earlier, and management expects higher interest expense in the second half as it evaluates refinancing options.
Regulatory risk remains another constraint. The December 2024 FDA warning letter is unresolved, and related Class III premarket approvals cannot be cleared until relevant violations are corrected. Braintree is producing SurgiMend, but its premarket approval still requires a successful pre-approval inspection.
IART’s Value Score Stands Out Amid Mixed Signals
The valuation case is clear, but the operating and balance-sheet risks keep the setup from becoming a simple low-multiple story. Earnings improvement and cost savings help, while modest sales growth, refinancing costs and FDA remediation limit visibility.
IART currently carries a Zacks Rank #3 (Hold). Its Value Score of B supports the discount argument, but the Growth Score of C, VGM Score of C and Momentum Score of D are less supportive. Because the Style Scores are designed to complement the Zacks Rank, the current mix favors a measured view rather than treating valuation alone as an unequivocal buy signal.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.